The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Vivimusta
Bendamustine Hydrochloride · BENDAMUSTINE HYDROCHLORIDE 25 mg/mL · Injection · Intravenous · Azurity Pharmaceuticals, Inc.
NDC 24338-0270-01 · 1 VIAL, MULTI-DOSE in 1 CARTON / 4 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Medicare Part B (ASP)
Payment limit per 1 MG
$29.913
HCPCS J9056 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2026 YTD · Q1)ⓘ
$52,058
11 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Latina Pharma S.P.AItalyanalysis · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA212209
- TE code
- —
- Approval date
- Dec 7, 2022
- Patents / exclusivity
- 4 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 12419867 | Jul 29, 2042 |
| patent | 12208086 | Jul 29, 2042 |
| patent | 11844784 | Jul 29, 2042 |
| patent | 11707450 | Jul 29, 2042 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Bendamustine Hydrochloride (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Avyxa Pharma, LLC | BENDAMUSTINE HYDROCHLORIDE 100 mg/4mL | Jul 15, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | BENDAMUSTINE HYDROCHLORIDE 25 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | BENDAMUSTINE HYDROCHLORIDE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eagle Pharmaceuticals, Inc | BENDAMUSTINE HYDROCHLORIDE 100 mg/4mL | Jul 15, 2026 | Sep 2, 2026 |
| Slayback Pharma LLC | BENDAMUSTINE HYDROCHLORIDE 25 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Vivimusta — NDC 24338-0270-01," retrieved September 3, 2026, https://drugdashboards.com/drug/24338027001.
Free to cite with attribution — see how the data is put together.